7 April 2016 - Boehringer Ingelheim today announced that the European Commission has granted marketing authorisation for Giotrif (afatinib dimaleate) for the treatment of patients with advanced squamous cell carcinoma (SqCC) of the lung whose disease has progressed on or after treatment with platinum-based chemotherapy.

Afatinib dimaleate is already approved for the treatment of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC).

For more details, go to: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2016/07_april_2016_oncology.html